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Summary. Pseudomonas aeruginosa is an opportunistic pathogen that produces sessile communities known as biofilms
that are highly resistant to antibiotic treatment. Limited information is available on the exact role of various components of
the matrix in biofilm-associated antibiotic resistance. Here we show that the presence of extracellular polysaccharide reduced
the extent of biofilm-associated antibiotic resistance for one class of antibiotics. Minimal bactericidal concentration (MBC)
for planktonic and biofilm cells of P. aeruginosa PA14 was measured using a 96 well microtiter plate assay. The MBC of
biofilm-grown ΔpelA mutant, which does not produce the Pel polysaccharide, was 4-fold higher for tobramycin and gentam-
icin, and unchanged for ΔbifA mutant, which overproduces Pel, when compared to the wild type. Biofilms of pelA mutants in
two clinical isolates of P. aeruginosa showed 4- and 8-fold higher MBC for tobramycin as compared to wild type. There was
no difference in the biofilm resistance of any of these strains when tested with fluoroquinolones. This work forms a basis for
future studies revealing the mechanisms of biofilm-associated antibiotic resistance to aminoglycoside antibiotics by P. aerug-
inosa. [Int Microbiol 2010; 13(4):207-212]
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Introduction
Pseudomonas aeruginosa is a ubiquitous gram-negative bac-
terium readily isolated from water and soil environments. It
is an opportunistic human pathogen frequently causing sep-
ticemia in burn patients, chronic infections in individuals
with cystic fibrosis, and urinary tract infections in catheter-
ized patients [7,9]. This organism can adopt a planktonic
(free swimming) or a biofilm mode of life. In response to
environmental cues, planktonic cells of P. aeruginosa adhere
to surfaces and adapt a sessile existence. Sessile cells prolif-
erate on surfaces, eventually differentiating to form struc-
tured communities called biofilms that are encased in a self-
produced matrix comprised of a variety of macromolecules,
including exopolysaccharides (EPS) [16].
Two different loci that contribute to the EPS component
of the matrix in non-mucoid P. aeruginosa strains have been
identified. The pel locus (referring to pellicle, a biofilm
formed at the air-medium interface), containing the genes
pelA-G, is responsible for synthesis of a glucose-rich compo-
nent of the matrix, whereas psl (polysaccharide synthesis
locus), containing the pslA-O genes, is responsible for a
mannose and galactose rich EPS [4–6,10,12]. It has been
suggested that exopolysaccharide matrix that surrounds the
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cells in the biofilm prevents diffusion of antimicrobial agents
to the microbes. While this reduced diffusion may be the case
for some antimicrobial agents, for others it has been shown
that antimicrobial agents can penetrate the matrix but still
cannot kill the cells in the biofilm [1,19]. In this report we
address the role of the Pel EPS in biofilm-associated antibi-
otic resistance of P. aeruginosa PA14 grown in a microtiter
well system.
Materials and methods
Bacterial strains, plasmids and media. Strains, plasmids and
primers used in the study are listed in Table 1. P. aeruginosa PA14 and
Escherichia coli were cultured on lysogeny broth (LB) medium [2] or min-
imal M63 salts supplemented with arginine (0.4%) and MgSO4 (1 mM) [11]. 
Molecular techniques. PCR amplification for 16SrRNA gene was carried
out for the two clinical isolates, isolated from an infected wound from a tertiary
care hospital of Pakistan, using primers listed in Table 1. The resulting sequences
were analyzed using the BLAST software and percentage similarity to other
sequences was determined. Presence of the pel genes was assayed in the clinical
isolates by PCR using primers listed in Table 1. The pelA mutation in two clini-
cal isolates was generated by a single-crossover (SCO) insertion using the
pMQ89 suicide vector as described by Kuchma et al. [8]. 
Antibiotic resistance assay. Ninety-six-well microtiter plate-based
assay was used to determine biofilm-specific antibiotic resistance as
described by Mah et al. [11], with slight modification. The minimal bacteri-
cidal concentrations for biofilm grown cells (MBC-B) was determined by
exposing 24 h-old biofilms to various concentrations of antibiotic for 24 h,
followed by a single wash of biofilms with sterile medium to remove the
antibiotics. Bacteria that survived antibiotic treatment were allowed to grow
for 24 h in fresh medium lacking antibiotics, and these bacteria subsequent-
ly were transferred to LB agar plate using a multipronged device to assess
growth. The MBC of planktonic bacteria (MBC-P) was determined by
adding antibiotic to bacteria at the time of inoculation, incubating for 24 h
followed by plating for viability. Both planktonic and biofilm populations
were comprised of ca. 1 × 107 colony forming units (CFU)/well.
Biofilm formation assay and assessment of EPS produc-
tion. Biofilm formation was measured using a microtiter dish system
described previously [3,15]. Congo red assays were performed as reported
[3,5,6]. Aliquotes of 2.5 µl of LB grown cultures were spotted onto the plates
for 24 h at 37oC followed by 3–4 days of incubation at room temperature. 
Results and Discussion
Loss of Pel EPS in lab strains does not lower
biofilm antibiotic resistance. For P. aeruginosa PA14
(referred to as PA14), the primary polysaccharide component
of the biofilm matrix in vitro is synthesized by the enzymes
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Table 1. Strains, plasmids and primers used in this study
Strain, plasmid, or primer Relevant genotype or sequence  (5′–3′) Source or reference 
Pseudomonas aeruginosa strains 
PA14 WT [17]
SMC3335 PA14ΔsadC [13] 
SMC2893 PA14ΔpelA [4,5]
SMC3351 PA14ΔbifA [8]
SMC3812 PA14ΔroeA [14]  
SMC3814 PA14ΔbifAΔroeA [14]  
SMC4685 Clinical isolate #99 from infected wound This study
SMC4687  SMC4685 pelA::pMQ89 This study
SMC4686 Clinical isolate #160 from infected wound This study
SMC4688 SMC4686 pelA::pMQ89 This study 
Plasmids 
pMQ89 Suicide cloning vector                                           [18]
Primers 
pelA-F GCTACGTGCCGTTCGTCAGCA
pelA-R CAGGCCGCCGAGGTAGACGTG
pelG-F TATTGCTGGCGACCCTGTTCGATG
pelG-R ATGAAACGCAGCAGGTAGGCACAG
16SrRNA-F AGAGTTTGATCCTGGCTCAG
16SrRNA-R ACGGGCGGTGTGTRC
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encoded by the pel locus. The Pel EPS is the cellular compo-
nent bound by the dye Congo Red (CR) [4,5]. Previous stud-
ies have shown that strains of PA14 with mutations in sadC,
pelA and roeA genes, as well as a double bifAroeA mutant
(Table 1) show a decrease in Pel-dependent polysaccharide
production compared to the wild type [13,14], while the
ΔbifA mutant shows increased pel-dependent polysaccharide
synthesis [8]. We tested biofilms formed by these mutants
and the wild type for their resistance to two different classes
of antibiotics using a 96 well dish biofilm assay. 
The MBC of biofilm (MBC-B)- and planktonically
(MBC-P)-grown wild type and mutants was determined for
gentamicin (an aminoglycoside antibiotic) and cipro-
floxacin (a fluoroquinolone antibiotic). No difference in
the planktonic MBC was observed between wild type and
the mutant strains for either of these antibiotics (Tables 2
and 3). 
Wild type biofilms showed a 4-fold higher MBC for
gentamicin when compared to planktonic cells. The
biofilm formed by the ΔbifA mutant had the same MBC for
gentamicin as that of wild type, indicating that increased
pel-derived polysaccharide production in ΔbifA does not
result in an increase in resistance (Table 2, left). Although
Pel polysaccharide produced by the ΔpelA, ΔsadC,
ΔbifAΔroeA and ΔroeA mutants was reduced as compared
to wild type, the MBC of these strains increased by 4-fold,
2-fold, 8-fold and 2-fold, respectively, for gentamicin.
For ciprofloxacin, the MBC-B was 8-fold higher for wild
type as compared to planktonic cells. In contrast to the stud-
ies using gentamicin, all the mutant strains tested for
ciprofloxacin showed the same MBC-B as that of wild type
(Table 3, left), indicating that the presence or absence of Pel
polysaccharide does not affect the resistance to cipro-
floxacin.
Loss of Pel EPS results in increased MBC for
aminoglycoside antibiotics in biofilms. To test
whether loss of Pel EPS has the same role in biofilm antibi-
otic resistance for other aminoglycoside and fluoroquinolone
antibiotics, as described above, we tested tobramycin (an
aminoglycoside) and ofloxacin (a fluoroquinolone). There
was no difference in MBC-P of wild type and the mutant
strains when tested against tobramycin and ofloxacin (Table
2 and 3, right).
A 4-fold higher MBC was observed for wild type biofilm
as compared to planktonic cells when tested for tobramycin.
P. AERUGINOSA BIOFILMS
Table 2. Resistance of planktonically and biofilm-grown strains to aminoglycoside antibiotics
Aminoglycosides
Gentamicin Tobramycin
Strains MBC-Pa Fold Change MBC-Ba Fold Change MBC-Pa Fold Change MBC-Ba Fold Change
PA14 39b _ 156b _ 19.5b _ 78b _   
ΔpelA 39b 1Xc 625b 4Xc 19.5b 1Xc 312.5b 4Xc
ΔbifA 39b 1Xc 156b 1Xc 19.5b 1Xc 78b 1Xc
ΔbifA ΔroeA 39b 1Xc 1250b 8Xc 19.5b 1Xc 625b 8Xc
ΔsadC 39b 1Xc 312.5b 2Xc 19.5b 1Xc 625b 8Xc
ΔroeA 39b 1Xc 312.5b 2Xc 19.5b 1Xc 625b 8Xc
SMC4685d 39b _ 312.5b _ 39b _ 156b _  
SMC4685 pelA::SCO NDe ND ND ND 39b 1Xc 1250b 8Xc
SMC4686d 39b _ 312.5b _ 39b _ 312.5b _ 
SMC4686 pelA::SCO ND ND ND ND 39b 1Xc 1250b 4Xc
a MBC-P (µg/ml), MBC of planktonically grown cells; MBC-B (µg/ml), MBC of biofilm-grown cells. b Values are from at least three separate experiments. 
c Fold-change compared to WT grown under the same conditions. d Clinical, non-mucoid P. aeruginosa isolate.
e ND, not determined.  As outlined in the text, the construct used to make this mutation confers gentamicin resistance and thus we could not determine bio-
film resistance to this antibiotic for these mutants. 
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As observed for the other aminoglycoside (gentamicin), the
MBC of biofilm-grown ΔbifA was the same as that of wild
type when tested for tobramycin. This confirmed that
increased production of Pel polysaccharide does not result in
an increase in antibiotic resistance to aminoglycosides. The
biofilm formed by the ΔpelA, ΔsadC, ΔbifAΔroeA and ΔroeA
mutants, all of which have lower Pel polysaccharide produc-
tion than the wild type, showed an increase in MBC for
tobramycin as compared to wild type (Table 2). Like cipro-
floxacin, the MBC-B for ofloxacin was the same for the wild
type and all mutants tested (Table 3). These data suggest that
at least for aminoglycoside antibiotics, loss of Pel polysac-
charide enhanced biofilm resistance of P. aeruginosa.
Clinical isolates defective for Pel polysaccha-
ride production display the same biofilm antibi-
otic resistance patterns as the PA14 lab strain.
In order to assess whether biofilm antibiotic resistance pat-
terns observed in lab strains was also observed in clinical iso-
lates, we repeated the assays described above with two clini-
cal, non-mucoid infected wound isolates of P. aeruginosa,
designated SMC4685 and SMC4686. 16SrRNA sequence
analysis was used to confirm that these isolates were P. aeru-
ginosa using primers listed in Table 1. These sequences
showed >99% similarity to other well characterized strains of
P. aeruginosa in Genbank. The pelA mutation was generated
by a single-crossover (SCO) insertion in the two clinical iso-
lates. The SCO insertion was confirmed by PCR, and these
mutants showed a decrease in CR binding and biofilm forma-
tion (Fig. 1). 
The MBC for planktonic and biofilm cells were measured
for the clinical isolates and for their pelA mutants for
ciprofloxacin, ofloxacin and tobramycin. Since the single
crossover insertion was generated using the suicide vector
pMQ89, which carries a gentamicin resistance marker, we
could not determine the MBC for gentamicin in the mutants
of the clinical isolates. For all the antibiotics tested, there was
no difference in the planktonic MBC of the pelA mutant and
their respective wild type for any of the antibiotics (Tables 2
and 3). Biofilms of the two clinical isolates SMC4685 and
SMC4686, respectively, showed a 4-fold and 8-fold higher
MBC for tobramycin as compared to planktonically grown
cells. The MBC of biofilm grown derivatives of the clinical
isolates, SMC4685 pelA::SCO and SMC4686 pelA::SCO,
was 8-fold and 4-fold higher for tobramycin when compared
to their respective wild type parent.
For these two clinical isolates, loss of Pel polysaccharide
production resulted in only a modest decrease in biofilm forma-
tion in the microtiter dish assay, which was not statistically sig-
nificant (Fig. 1B). Thus, these strains showed increased biofilm
resistance despite a small, non-significant decrease in total bio-
film formation. Like the PA14 lab strain, both the clinical isolates
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Table 3. Resistance of planktonically and biofilm-grown strains to fluoroquinolones antibiotics
Fluoroquinolone
Ciprofloxacin Ofloxacin 
Strains MBC-Pa Fold Change MBC-Ba Fold Change MBC-Pa Fold Change MBC-Ba Fold Change
PA14 3.9b _ 31.25b _ 62.5b _ 250b _
ΔpelA 3.9b 1Xc 31.25b 1Xc 62.5b 1Xc 250b 1Xc
ΔbifA 3.9b 1Xc 31.25b 1Xc 62.5b 1Xc 250b 1Xc
ΔbifA ΔroeA 3.9b 1Xc 31.25b 1Xc 62.5b 1Xc 250b 1Xc
ΔsadC 3.9b 1Xc 31.25b 1Xc 62.5b 1Xc 250b 1Xc
ΔroeA 3.9b 1Xc 31.25b 1Xc 62.5b 1Xc 250b 1Xc
SMC4685d 0.9b _ 31.25b _ 7.8b _ 62b _ 
SMC4685 pelA::SCO 0.9b 1Xc 31.25b 1Xc 7.8b 1Xc 62b 1Xc
SMC4686d 1.8b _ 31.25b _ 7.8b _ 250b _ 
SMC4686 pelA::SCO 1.8b 1Xc 31.25b 1Xc 7.8b 1Xc 250b 1Xc
a MBC-P (µg/ml), MBC of planktonically grown cells; MBC-B (µg/ml), MBC of biofilm-grown cells. b Values are based from results from at least three sepa-
rate experiments. c Fold-change compared to WT grown under the same conditions. d Clinical, non-mucoid P. aeruginosa isolate.
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showed no difference in the MBC-B of pelA mutants and their
respective wild type when tested for fluoroquinolone resistance.
In conclusion, here we present evidence that presence of
Pel polysaccharide is not important for biofilm antibiotic
resistance of P. aeruginosa under the conditions tested in
this report, that is, in biofilms grown in microtiter dishes.
Our data show that biofilm antibiotic resistance increases for
aminoglycosides when the Pel polysaccharide is reduced in
both lab and clinical isolates of P. aeruginosa. Furthermore,
the degree of increased biofilm resistance measured in these
Pel-deficient mutants is likely somewhat of an under-estima-
tion given that these mutants typically show some decrease
in biofilm formation [13,14]. It is possible that the pelA
mutants produce a second EPS molecule, which might help
explain our findings. Alternatively, it is possible that
decreasing pel-dependent polysaccharide might result in a
compensatory up-regulation of other factors that either
directly or indirectly cause the observed resistance. A more
detailed study of the role of Pel polysaccharide in biofilm
antibiotic resistance will be necessary to address questions
arising from this work. 
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